Phase 1/2a Dose Escalation Study in Participants with CLL, SLL, or NHL

Study identifier:13-601

ClinicalTrials.gov identifier:NCT01994382

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase 1/2a Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell or T-Cell Non-Hodgkin Lymphoma (NHL)

Medical condition

Follicular Lymphoma (FL/Indolent NHL)

Phase

Phase 1/2

Healthy volunteers

No

Study drug

Cerdulatinib

Sex

All

Actual Enrollment

260

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 30 Aug 2013
Primary Completion Date: 15 Dec 2020
Study Completion Date: 15 Dec 2020

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2024 by Alexion Pharmaceuticals, Inc.

Sponsors

Alexion Pharmaceuticals, Inc.

Collaborators

Portola Pharmaceuticals

Inclusion and exclusion criteria